In the evolving field of interventional psychiatry and neuromodulation, researchers are looking for ways to make treatments smarter, more efficient and personalized. One such path involves the search for a quantitative EEG biomarker for rTMS response, and this article explains what that means, why it matters, and what recent research is showing.
What Is A Quantitative EEG Biomarker For rTMS Response?
A biomarker is a measurable biological feature that gives information about a condition or a likely outcome. In this case, “quantitative EEG” (qEEG) refers to numerical analysis of brain-wave recordings (electroencephalography = EEG). The idea is to use qEEG measures to predict how well a person will respond to treatment with repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain-stimulation technique. If successful, a quantitative EEG biomarker for rTMS response could signal ahead of time which patients are likely to benefit and which may not.
Why Does This Matter?
rTMS is already used in several contexts (for depression, cognitive impairment, etc.), but the response rate is variable, the cost can be high, and the time commitment significant. Being able to predict who will respond means more efficient use of resources, less wasted treatments, and better outcomes for patients. The search for a reliable quantitative EEG biomarker for rTMS response is therefore a key step toward precision neuromodulation.
What Do Recent Studies Show?
One recent pilot trial protocol, published in 2025, specifically aims to identify a quantitative EEG biomarker for rTMS response in people with mild cognitive impairment (MCI). That study plans to enroll older adults (60 +), record their EEG, and then give 10 sessions of rTMS over two weeks. Participants will be classified as responders (based on cognitive test improvement) or non-responders, and their baseline qEEG compared.
Another line of research shows that qEEG in MCI and early dementia already detects changes: for example slower dominant frequency, increased theta/pre alpha power, and reduced beta power. These changes suggest that EEG biomarkers are sensitive to underlying brain changes and by extension may help in treatment prediction.
How Could This Work in Clinical Practice?
Imagine a patient with MCI or early cognitive decline. Before starting rTMS, their EEG is recorded and analysed for specific qEEG features (for example, dominance of slower-wave power rather than faster beta waves). If the quantitative EEG biomarker for rTMS response has been validated, the clinician could use that result to decide: this patient has a high probability of improving with rTMS; or perhaps their likelihood is low and we should consider alternate treatments. This kind of predictive approach saves time, money, and helps avoid exposing patients to ineffective treatments.
What Are The Challenges Ahead?
Several remain. First, the biomarker must be validated in larger, diverse populations and different centers (so it works beyond one lab). The pilot trial mentioned is small (25 participants) and over a short duration. Also, standardization of EEG acquisition, processing and metrics is needed, as “quantitative EEG” can mean many things, and variability can undermine reliability. The review on qEEG biomarkers in Alzheimer’s and MCI notes these issues. Finally, prediction is one thing; integration into actual treatment workflows (clinics, reimbursement, training) is another.
What Does The Future Look Like?
If a valid quantitative EEG biomarker for rTMS response becomes established, we could see a shift toward personalized neuromodulation, where EEG screening guides who gets rTMS, how often, and perhaps at what parameters (frequency, brain target, pulse count). For patients with cognitive decline or psychiatric disorders, this means smarter use of brain-stimulation technology. For clinicians and researchers, this opens new research avenues (which EEG features matter most? how to combine EEG with imaging or genetic data?). For patients and families, this means hope for more targeted, effective interventions.
Final Thoughts
The search for a quantitative EEG biomarker for rTMS response is a promising frontier in the world of neuromodulation and interventional psychiatry. It brings together brain-wave monitoring, individualized treatment planning and cost effectiveness. While still early, emerging research suggests we are moving closer to a future where EEG guided brain stimulation becomes part of standard care. At the intersection of neuroscience, psychiatry and technology, this approach may help bring the right treatment to the right patient at the right time.
Citations:
- Yousefian Z, Hosseini SH, Nazari MA et al. Quantitative Electroencephalographic Biomarkers for Repetitive Transcranial Magnetic Stimulation Treatment Response Prediction in Mild Cognitive Impairment: A Pilot Study Protocol for Multi-Center, Assessor-Blinded, Open-Label Clinical Trial. Brain Behav. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12577763/
- Yuan Y et al. The role of quantitative EEG biomarkers in Alzheimer’s and MCI: non-invasive monitoring of brain dynamics. Front Aging Neurosci. 2025. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2025.1522552/full